keyword
MENU ▼
Read by QxMD icon Read
search

Chondrosarcoma

keyword
https://www.readbyqxmd.com/read/29146595/the-cartilage-specific-lectin-c-type-lectin-domain-family-3-member-a-clec3a-enhances-tissue-plasminogen-activator-mediated-plasminogen-activation
#1
Daniela Lau, Dzemal Elezagic, Gabriele Hermes, Matthias Mörgelin, Alexander P Wohl, Manuel Koch, Ursula Hartmann, Stefan Höllriegl, Raimund Wagener, Mats Paulsson, Thomas Streichert, Andreas R Klatt
C-type lectin domain family 3 member A (CLEC3A) is a poorly characterized protein belonging to the superfamily of C-type lectins. Its closest homologue tetranectin binds to the kringle 4 domain of plasminogen and enhances its association with tissue plasminogen activator (tPA) thereby enhancing plasmin production, but whether CLEC3A contributes to plasminogen activation is unknown. Here, we recombinantly expressed murine and human full-length CLEC3As as well as truncated forms of CLEC3A in HEK-293 EBNA cells...
November 16, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29146074/corrigendum-to-diagnostic-utility-of-idh1-2-mutations-to-distinguish-dedifferentiated-chondrosarcoma-from-undifferentiated-pleomorphic-sarcoma-of-bone-hum-pathol-2017-65-239-46
#2
Shaoxiong Chen, Karen Fritchie, Shi Wei, Naser Ali, Kendra Curless, Tiansheng Shen, Anna T Brini, Farida Latif, Vaiyapuri Sumathi, Gene P Siegal, Liang Cheng
No abstract text is available yet for this article.
November 13, 2017: Human Pathology
https://www.readbyqxmd.com/read/29143958/intraspinal-mesenchymal-chondrosarcoma-report-of-a-pediatric-case-and-literature-review
#3
Angela Di Giannatale, Marta Colletti, Ida Russo, Valentina Ferruzzi, Vito Andrea Dell' Anna, Raffaele Cozza, Giovanna Stefania Colafati, Raffaella Messina, Angela Mastronuzzi, Rita De Vito, Giuseppe Maria Milano
PURPOSE: Mesenchymal chondrosarcoma (MCS) is an aggressive variant of chondrosarcoma and is a rare tumor, particularly within the pediatric population. Commonly, MCS originates in the bone, but it can also arise in extraskeletal sites, such as the brain and the intraspinal area. Due to the rarity of this tumor, there are no guidelines for its optimal treatment. METHODS: We report a case of intradural extramedullary MCS, located at the T11-T12 level, in a 14-year-old male...
November 15, 2017: Tumori
https://www.readbyqxmd.com/read/29138803/toll-like-receptors-tlr1-2-tlr6-and-muc5b-as-binding-interaction-partners-with-cytostatic-proline-rich-polypeptide-1-in-human-chondrosarcoma
#4
Karina Galoian, Silva Abrahamyan, Gor Chailyan, Amir Qureshi, Parthik Patel, Gil Metser, Alexandra Moran, Inesa Sahakyan, Narine Tumasyan, Albert Lee, Tigran Davtyan, Samvel Chailyan, Armen Galoyan
Metastatic chondrosarcoma is a bone malignancy not responsive to conventional therapies; new approaches and therapies are urgently needed. We have previously reported that mTORC1 inhibitor, antitumorigenic cytostatic proline rich polypeptide 1 (PRP-1), galarmin caused a significant upregulation of tumor suppressors including TET1/2 and SOCS3 (known to be involved in inflammatory processes), downregulation of oncoproteins and embryonic stem cell marker miR-302C and its targets Nanog, c-Myc and Bmi-1 in human chondrosarcoma...
November 9, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29135804/surgical-management-of-tumors-involving-meckel-s-cave-and-cavernous-sinus-role-of-an-extended-middle-fossa-and-lateral-sphenoidectomy-approach
#5
Daniel Q Sun, Arnold H Menezes, Matthew A Howard, Bruce J Gantz, David M Hasan, Marlan R Hansen
OBJECTIVE: To study the indications and outcomes of lateral sphenoidectomy as part of a combined skull base approach in the treatment of tumors involving Meckel's cave (MC) and cavernous sinus (CS). STUDY DESIGN: Retrospective patient series. SETTING: Tertiary referral center. PATIENTS: Twenty-two consecutive patients (mean age: 45 yr, range: 16-76) who underwent transzygomatic, extended middle fossa approaches for tumors involving MC and CS...
November 13, 2017: Otology & Neurotology
https://www.readbyqxmd.com/read/29131675/dedifferentiated-chondrosarcoma-in-the-dog-and-cat-a-case-series-and-review-of-the-literature
#6
Arathi Vinayak, Deanna R Worley, Stephen J Withrow, Dustin S Adams, Barbara E Powers
This retrospective case series describes seven dogs and one cat diagnosed with dedifferentiated chondrosarcoma, an uncommon, aggressive variant of chondrosarcoma. The purpose of the study is to describe clinical, imaging, and histopathological findings of this tumor. Medical records and the diagnostic laboratory database at Colorado State University from 2000 to 2015 were reviewed and complete medical records were available for the eight animals in this report. Similar to what has been reported in people, poor long-term survival and high metastatic rate, particularly to the lungs, was observed in our case series...
November 13, 2017: Journal of the American Animal Hospital Association
https://www.readbyqxmd.com/read/29123414/low-grade-central-osteosarcoma-in-proximal-humerus-a-rare-entity
#7
Fan Tang, Li Min, Yong Zhou, Yi Luo, Chongqi Tu
Low-grade central osteosarcoma is a rare subtype of tumor with low-grade malignancy. Currently, wide resection with negative resection margin is the standard treatment for this disease. The role of neoadjuvant chemotherapy in low-grade central osteosarcoma was controversial and was mostly considered for tumors containing high-grade focal areas. Local tumor recurrences often exhibited a tumor with higher histologic grade or differentiation with the potential for metastases. In low-grade central osteosarcoma, timely wide resection after definite diagnosis can result in 5-year survival for almost 90%...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29114282/multicompartmental-primary-spinal-extramedullary-tumors-value-of-an-interdisciplinary-approach
#8
Guruprasad Bettaswamy, Paurush Ambesh, Raj Kumar, Rabi Narayan Sahu, Kuntal Kanti Das, Awadhesh Kumar Jaiswal, Arun Kumar Srivastava, Sanjay Behari
Background: Primary extramedullary tumors involving multiple compartments around the spine are a technically demanding group of tumors whose extent traverses beyond the normal confines of those anatomical regions which fall in the common domain of neurosurgeons. In the following series, we present 12 patients who were diagnosed with primary spinal extramedullary tumors with multicompartmental extension, and whose surgical management was facilitated by a combined multidisciplinary approach involving surgeons of other superspecialties...
October 2017: Asian Journal of Neurosurgery
https://www.readbyqxmd.com/read/29113853/hyperkinetic-transient-ischemic-attacks-preceding-deep-ganglionic-infarction-in-a-patient-with-a-treated-parasellar-chondrosarcoma
#9
Michael W Ruff, Adip G Bhargav, Stephen W English, James P Klaas
A 44-year-old right-handed female with a past medical history of parasellar chondrosarcoma status post-surgical debulking and proton beam therapy (70 Gy) three years prior to presentation experienced several hours of brief, repetitive episodes of transient hemiballism and dystonia; this was followed by abrupt onset of fixed hemiparesis and dysarthria weeks later, ipsilateral to her prior hyperkinetic movements. She was found to have total occlusion of the right middle cerebral artery with focal stenosis of the proximal right A-1 segment of the anterior cerebral artery adjacent to the remnants of the chondrosarcoma...
November 4, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/29113210/analysis-of-imaging-characteristics-of-primary-malignant-bone-tumors-in-children
#10
Yingwei Sun, Xueyong Liu, Shinong Pan, Chunbo Deng, Xiaohan Li, Qiyong Guo
The present study aimed to investigate the imaging characteristics of primary malignant bone tumors in children. The imaging results of 34 children with primary malignant bone tumors confirmed by histopathological diagnosis between March 2008 and January 2014 were retrospectively analyzed. In total, 25 patients had osteosarcoma, with radiography and computed tomography (CT) showing osteolytic bone destruction or/and osteoblastic bone sclerosis, an aggressive periosteal reaction, a soft-tissue mass and cancerous bone...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29113186/puerarin-induces-cell-apoptosis-in-human-chondrosarcoma-cell-line-sw1353-via-inhibition-of-the-pi3k-akt-signaling-pathway
#11
Li Huang, Junqing Cao, Lan Cao, Ling Gao, Ying Yang, Li Xu
Chondrosarcoma is a malignant soft tissue sarcoma with poor prognosis. Puerarin has been demonstrated to possess anticancer properties; however, the effects of puerarin in human chondrosarcoma cells remain unknown. The present study aimed to investigate the anticancer effects of puerarin in SW1353 human chondrosarcoma cells. SW1353 cells were treated with increasing concentrations of puerarin for different durations. Cell viability was evaluated using MTT assays. Cell apoptosis rates were determined by flow cytometry...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29100385/histone-deacetylase-inhibitors-vorinostat-and-panobinostat-induce-g1-cell-cycle-arrest-and-apoptosis-in-multidrug-resistant-sarcoma-cell-lines
#12
Eva Bernhart, Nicole Stuendl, Heike Kaltenegger, Christian Windpassinger, Nicholas Donohue, Andreas Leithner, Birgit Lohberger
Synovial sarcoma and high grade chondrosarcoma are characterized by their lack of response to conventional cytotoxic chemotherapy, the tendency to develop lung metastases, and low survival rates. Research within the field prioritizes the development and expansion of new treatment options for dealing with unresectable or metastatic diseases. Numerous clinical trials using histone deacetylases inhibitors (HDACi) have shown specific efficacy as an active antitumor agent for treating a variety of solid tumors. However, as of yet the effect of different HDACi on synovial- and chondrosarcoma cells has not been investigated...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29091320/suppression-of-hyaluronan-synthesis-attenuates-the-tumorigenicity-of-low-grade-chondrosarcoma
#13
Shunsuke Hamada, Yoshihiro Nishida, Lisheng Zhuo, Tamayuki Shinomura, Kunihiro Ikuta, Eisuke Arai, Hiroshi Koike, Koji Kimata, Takahiro Ushida, Naoki Ishiguro
Hyaluronan (HA) has been shown to play crucial roles in the tumorigenicity of malignant tumors. Chondrosarcoma, particularly when low-grade, is characterized by the formation of an extracellular matrix (ECM) containing abundant HA, and its drug/radiation resistance has become a clinically relevant problem. This study aimed to evaluate the effects of an HA synthesis inhibitor, 4-methylumbelliferone (MU), on ECM formation as well as antitumor effects in chondrosarcoma. We investigated the effects of MU on rat chondrosarcoma (RCS) cells with a grade I histological malignancy in vitro and in vivo grafted model...
November 1, 2017: Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society
https://www.readbyqxmd.com/read/29079234/primary-tumor-and-tumor-like-lesions-of-bones-of-the-foot-single-center-experience-of-166-cases
#14
Devrim Özer, Osman Emre Aycan, Sait Turgay Er, Rahime Tanrıtanır, Yavuz Arıkan, Yavuz Selim Kabukçuoğlu
Primary bone tumors of the foot are rare lesions. The purpose of the present study was to evaluate the clinical manifestations, treatment modalities, and recurrences of various primary bone tumors of the foot from a specialized center for orthopedic oncology. Among 3681 musculoskeletal tumor cases, which were diagnosed and surgically treated in our hospital from 1983 to 2013, 166 primary tumor and tumor-like bone lesions of the foot (4.5%) were retrospectively reviewed regarding age, gender, localization, biopsy-revealed diagnosis, applied treatment modalities, follow-up period, and recurrence, if any...
November 2017: Journal of Foot and Ankle Surgery: Official Publication of the American College of Foot and Ankle Surgeons
https://www.readbyqxmd.com/read/29056515/in%C3%A2-vivo-imaging-of-glutamine-metabolism-to-the-oncometabolite-2-hydroxyglutarate-in-idh1-2-mutant-tumors
#15
Lucia Salamanca-Cardona, Hardik Shah, Alex J Poot, Fabian M Correa, Valentina Di Gialleonardo, Hui Lui, Vesselin Z Miloushev, Kristin L Granlund, Sui S Tee, Justin R Cross, Craig B Thompson, Kayvan R Keshari
The oncometabolite 2-hydroxyglutarate (2-HG) is a signature biomarker in various cancers, where it accumulates as a result of mutations in isocitrate dehydrogenase (IDH). The metabolic source of 2-HG, in a wide variety of cancers, dictates both its generation and also potential therapeutic strategies, but this remains difficult to access in vivo. Here, utilizing patient-derived chondrosarcoma cells harboring endogenous mutations in IDH1 and IDH2, we report that 2-HG can be rapidly generated from glutamine in vitro...
October 16, 2017: Cell Metabolism
https://www.readbyqxmd.com/read/29052449/resveratrol-in-management-of-bone-and-spinal-cancers
#16
Gang Chen, Hong Xia, Zhi-Guo Zhang, Hai-Liang Yu
Bone cancer is a malignant primary tumour of the bone with different typing, such as, osteosarcoma, chondrosarcoma, Ewing's sarcoma and fibrosarcoma. Despite the clinical efficacy of conventional therapies of bone cancer, most patients eventually relapse and the disease remains incurable. Therefore, new therapeutic strategies are needed to improve patient outcome. In this review article, we have discussed the role of resveratrol in preventing bone and spinal cancers and therapeutics. Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a natural polyphenol, which has been widely reported as an anticancer molecule...
October 20, 2017: Natural Product Research
https://www.readbyqxmd.com/read/29044531/mesenchymal-chondrosarcoma-a-japanese-musculoskeletal-oncology-group-jmog-study-on-57-patients
#17
Yusuke Tsuda, Koichi Ogura, Michiyuki Hakozaki, Kazutaka Kikuta, Keisuke Ae, Hiroyuki Tsuchiya, Shintaro Iwata, Takafumi Ueda, Hirotaka Kawano, Akira Kawai
BACKGROUND: This study aimed to elucidate the clinical features and prognostic factors of mesenchymal chondrosarcoma (MCS) and investigate optimal treatment strategies. METHODS: Data from 57 patients with MCS were collected from a Japanese Musculoskeletal Oncology Group (JMOG) and retrospectively analyzed. RESULTS: Data from 29 males and 28 females were collected. Primary tumor sites were the head and neck (7 patients), trunk (35 patients), and extremities (15 patients)...
May 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29044189/tgf-%C3%AE-signalling-and-peg10-are-mutually-exclusive-and-inhibitory-in-chondrosarcoma-cells
#18
Naohiro Shinohara, Shingo Maeda, Yuhei Yahiro, Daisuke Sakuma, Kanehiro Matsuyama, Katsuyuki Imamura, Ichiro Kawamura, Takao Setoguchi, Yasuhiro Ishidou, Satoshi Nagano, Setsuro Komiya
Histological distinction between enchondroma and chondrosarcoma is difficult because of a lack of definitive biomarkers. Here, we found highly active transforming growth factor-β (TGF-β) and bone morphogenetic protein (BMP) signalling in human chondrosarcomas compared with enchondromas by immunohistochemistry of phosphorylated SMAD3 and SMAD1/5. In contrast, the chondrogenic master regulator SOX9 was dramatically down-regulated in grade 1 chondrosarcoma. Paternally expressed gene 10 (PEG10) was identified by microarray analysis as a gene overexpressed in chondrosarcoma SW1353 and Hs 819...
October 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29040684/multimodality-treatment-of-skull-base-chondrosarcomas-the-role-of-histology-specific-treatment-protocols
#19
(no author information available yet)
No abstract text is available yet for this article.
October 13, 2017: Neurosurgery
https://www.readbyqxmd.com/read/29038849/malignant-bone-tumors-other-than-ewing-s-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up-by-spanish-group-for-research-on-sarcomas-geis
#20
Andrés Redondo, Silvia Bagué, Daniel Bernabeu, Eduardo Ortiz-Cruz, Claudia Valverde, Rosa Alvarez, Javier Martinez-Trufero, Jose A Lopez-Martin, Raquel Correa, Josefina Cruz, Antonio Lopez-Pousa, Aurelio Santos, Xavier García Del Muro, Javier Martin-Broto
Primary malignant bone tumors are uncommon and heterogeneous malignancies. This document is a guideline developed by the Spanish Group for Research on Sarcoma with the participation of different specialists involved in the diagnosis and treatment of bone sarcomas. The aim is to provide practical recommendations with the intention of helping in the clinical decision-making process. The diagnosis and treatment of bone tumors requires a multidisciplinary approach, involving as a minimum pathologists, radiologists, surgeons, and radiation and medical oncologists...
October 16, 2017: Cancer Chemotherapy and Pharmacology
keyword
keyword
7654
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"